Although we did not observe a significant distinction in tumor-specific mutations between the CCL4 high and low groups, we proposed that CCL4 could reflect the level of the TMB, on the other hand, the TMB might synergistically serve with CCL4 as a predominant prognostic signature related to novel therapeutic targets in ccRCC. Here, CCL4 is linked to nonpapillary renal cell carcinoma.